IN2015DN01967A - - Google Patents

Info

Publication number
IN2015DN01967A
IN2015DN01967A IN1967DEN2015A IN2015DN01967A IN 2015DN01967 A IN2015DN01967 A IN 2015DN01967A IN 1967DEN2015 A IN1967DEN2015 A IN 1967DEN2015A IN 2015DN01967 A IN2015DN01967 A IN 2015DN01967A
Authority
IN
India
Prior art keywords
antibody
compared
reduced immunogenicity
anti tnf
reference antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Fiona A Harding
Olivia Jennifer Razo
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of IN2015DN01967A publication Critical patent/IN2015DN01967A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1967DEN2015 2012-09-19 2013-09-18 IN2015DN01967A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
IN2015DN01967A true IN2015DN01967A (OSRAM) 2015-08-14

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1967DEN2015 IN2015DN01967A (OSRAM) 2012-09-19 2013-09-18

Country Status (27)

Country Link
US (1) US9279016B2 (OSRAM)
EP (2) EP3211006A3 (OSRAM)
JP (1) JP2015537190A (OSRAM)
KR (1) KR20150056788A (OSRAM)
CN (1) CN104704000A (OSRAM)
AU (1) AU2013318147B2 (OSRAM)
BR (1) BR112015005857A2 (OSRAM)
CA (1) CA2885422A1 (OSRAM)
CY (1) CY1118893T1 (OSRAM)
DK (1) DK2897978T3 (OSRAM)
ES (1) ES2621285T3 (OSRAM)
HR (1) HRP20170937T1 (OSRAM)
HU (1) HUE032569T2 (OSRAM)
IL (1) IL237833A0 (OSRAM)
IN (1) IN2015DN01967A (OSRAM)
LT (1) LT2897978T (OSRAM)
MX (1) MX2015003541A (OSRAM)
NZ (1) NZ705606A (OSRAM)
PL (1) PL2897978T3 (OSRAM)
PT (1) PT2897978T (OSRAM)
RS (1) RS56093B1 (OSRAM)
RU (1) RU2648141C2 (OSRAM)
SG (1) SG11201502094TA (OSRAM)
SI (1) SI2897978T1 (OSRAM)
SM (1) SMT201700255T1 (OSRAM)
TW (1) TWI519646B (OSRAM)
WO (1) WO2014047222A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位,含此表位的多抗原肽及应用
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN110382696B (zh) * 2017-03-07 2024-04-19 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
TW202039554A (zh) * 2018-12-19 2020-11-01 瑞士商諾華公司 抗TNF-α抗體
CN114401988A (zh) * 2019-07-09 2022-04-26 国家生物技术研究所公司 具有降低的免疫原性的抗体
JP2022550390A (ja) 2019-09-30 2022-12-01 スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング iRhom2エピトープに結合するタンパク質バインダー
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
BR112023017035A2 (pt) 2021-03-01 2024-02-06 New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
EP4568997A1 (en) 2022-08-08 2025-06-18 ATB Therapeutics Humanized antibodies against cd79b
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0189330B1 (en) 1985-01-25 1992-12-02 The Kitasato Institute Antitumor antibiotics and their production
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
RO123028B1 (ro) * 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
PL1725249T3 (pl) 2003-11-06 2014-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do ligandów
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗egfr抗体
US8969024B2 (en) * 2007-08-28 2015-03-03 Abbvie Biotechnology Ltd Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝF-α 항체 및 그의 용도
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
CA2792740A1 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation Antibodies with ph dependent antigen binding
RU2584597C2 (ru) * 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
BR112013009551A2 (pt) * 2010-10-20 2016-07-12 Oxford Biotherapeutics Ltd anticorpos

Also Published As

Publication number Publication date
CY1118893T1 (el) 2018-01-10
CA2885422A1 (en) 2014-03-27
US9279016B2 (en) 2016-03-08
LT2897978T (lt) 2017-06-12
PL2897978T3 (pl) 2017-08-31
DK2897978T3 (en) 2017-05-15
TW201418469A (zh) 2014-05-16
WO2014047222A3 (en) 2014-10-23
PT2897978T (pt) 2017-05-22
RS56093B1 (sr) 2017-10-31
JP2015537190A (ja) 2015-12-24
US20140227251A1 (en) 2014-08-14
AU2013318147A1 (en) 2015-03-19
KR20150056788A (ko) 2015-05-27
NZ705606A (en) 2018-05-25
CN104704000A (zh) 2015-06-10
EP3211006A3 (en) 2017-11-08
RU2015111671A (ru) 2016-11-10
SMT201700255T1 (it) 2017-07-18
IL237833A0 (en) 2015-05-31
WO2014047222A9 (en) 2014-06-26
MX2015003541A (es) 2015-10-26
EP3211006A2 (en) 2017-08-30
BR112015005857A2 (pt) 2017-08-08
EP2897978A2 (en) 2015-07-29
EP2897978B1 (en) 2017-03-22
TWI519646B (zh) 2016-02-01
SG11201502094TA (en) 2015-04-29
ES2621285T3 (es) 2017-07-03
HUE032569T2 (en) 2017-09-28
RU2648141C2 (ru) 2018-03-22
WO2014047222A2 (en) 2014-03-27
SI2897978T1 (sl) 2017-05-31
HRP20170937T1 (hr) 2017-11-03
AU2013318147B2 (en) 2018-01-04
HK1211306A1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
IN2015DN01967A (OSRAM)
IL234885A0 (en) Methods to improve diaphragm function
IN2014CN02639A (OSRAM)
IL228001B (en) Antibodies to 70cd
AU2013316100A1 (en) Antibody evolution immunogens
IL233694A0 (en) Antibodies against cxcr3
EP2855529A4 (en) HUMANIZED ANTI-FACTOR B ANTIBODIES
GB201207235D0 (en) Fuel pump assembly
ZA201406703B (en) Improved injections
EP2877886A4 (en) OPTICAL MOTOR
EP2804876A4 (en) NEW ANTIBODIES
GB201212703D0 (en) Transactional account repository
EP2695133A4 (en) IDENTIFICATION OF SIMILARITIES
IN2012DE02272A (OSRAM)
GB201218066D0 (en) Optoelectronic assembly
LT2750136T (lt) Kuro rinklė
UA72478U (ru) Применение полентара как средства фригопротекторного действия
GB201210772D0 (en) Novel lighting methods
GB201202794D0 (en) Fuel economy patent abstract
UA80618U (en) Use of n-steroylethanolamine as radiomodifier